Disease management
The virtual opioid use disorder company reached profitability in Q4 2024, and expanded its team with the appointments of a chief operating officer and chief financial officer.
PanopticAI also claims to be the first in the city to obtain US FDA clearance for software as a medical device.
The company will use the funds to expand access to its hormonal healthcare platform across the U.S.
The partnership gives Lantern clients entry into customized substance use disorder treatment and telemedicine services.
The financing will be used to execute the company's long-term growth initiatives centered on high-margin, scalable recurring revenues across B2B and pharma channels.
Also, Aevice Health from Singapore has obtained new investment for its global expansion.
This model, developed by the Chinese University of Hong Kong and Beijing Tongren Hospital, is now being deployed across China's Henan Province to diagnose common eye diseases.
Century Health’s AI platform will create structured datasets based on multiple sclerosis patient data collected from Nira Medical’s network of clinics.
The alliance will result in the integration of transcriptome genomic data from Scipher's PrismRA Test into OMNY Health's EHR network.
A Singaporean startup leverages Asian-specific databases in making heart disease risk assessments.